Healthcare news

Here are the 4 big things we're watching in the stock market in the week ahead

Both sides of the Fed's dual mandate are in focus. Plus, Micron reports and Eli Lilly delivers updates on its obesity pipeline.

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Pharma stock soars 150% on injectables deal with Wegovy maker Novo

Shares in Swedish microcap stock Nanexa more than doubled after the drug-delivery group revealed a licensing deal with European pharma giant Novo Nordisk.

November 6th Options Now Available For Pfizer (PFE)

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the November 6th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options chain for the new November 6th…

Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Noteworthy Wednesday Option Activity: UNH, ALGN, URI

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in UnitedHealth Group Inc (Symbol: UNH), where a total of 30,870 contracts have traded so far, representing approximately 3.1 million…

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.

Humana vs UnitedHealth: valuation, profitability, and earnings momentum compared

Stocks making the biggest moves midday: Lennar, Capri, Vicor, Amgen & more

These are the stocks posting the largest moves midday.

XLV, PFE, BMY, DHR: Large Outflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street Health Care Select Sector SPDR ETF (Symbol: XLV) where we have detected an approximate $219.7…

Novo defends diversification push as CEO eyes deals beyond obesity

Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.

Eli Lilly CEO offers investors 3 more reasons to stick with the stock

Encouraging updates from Eli Lilly CEO Dave Ricks strengthen the bull case for the stock.

Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy

The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.

Moderna will reveal the data for its mRNA cancer vaccine next month. Here’s why it matters.

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

Novo’s Big 2030 Pitch Gets a Small Reception

Dow Jones Futures Due: Can The Market Take Flight? Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas

Dow Jones Futures: Can The Market Rally Take Flight? Robinhood, Sandisk, AMD, Moderna Surge Into Buy Areas

Novo CEO Says Drugmaker Needs to “Rethink” its Obesity Strategy

Gilead Strengthens HIV Growth Platform with Expanded Latin America Access

Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial

Twist Bioscience stock rises on Eli Lilly partnership deal

Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift

Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 Caveat

How UnitedHealth (UNH) Leads the AI Revolution in the Insurance Industry

Lilly’s Foundayo Quickly Gains Ground in the Oral Weight-Loss Market

From Novo Nordisk to ‘Novo’: A Strategic Reset Amid Rising Lilly Pressure

Lilly says Foundayo has captured over 30% of new US patients on oral weight-loss drugs

Blackrock Moves Up In Market Cap Rank, Passing Pfizer

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Blackrock Inc (Symbol: BLK) has taken over the #77 spot from Pfizer Inc (Symbol: PFE), according to The Online Investor. Market…

Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' obesity strategy

The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.

Novo Nordisk is changing its name and its culture to try to compete in the GLP-1 diet-drug wars

The Danish drug giant behind Ozempic is competing with Eli Lilly in the market for weight-loss drugs.

Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question.

Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test

Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense Stock

Dow Jones Futures: Fed Rate Hike Seen As Oil, Yields Pressure Stocks; Apple, Moderna Are New Buys

AstraZeneca breast cancer drug fails late-stage trial goal

Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca

3 Top Dividend Aristocrats To Own Near All-Time Highs

Several Dividend Aristocrats, including Johnson & Johnson (JNJ), Coca-Cola (KO), and Exxon Mobil (XOM), are trading near all-time highs, reflecting bullish momentum driven by strong results or favorable operating conditions.

Drug Trial Setbacks Raise Questions Over Novartis (NVS)’s Growth Pipeline

Dow Movers: AMGN, HONIV

In early trading on Friday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the…

Why is Amgen stock sliding today?

UnitedHealth Reshapes Florida WellMed Operations With TPG Deal

UNH's TPG deal brings local support and investment to Florida WellMed clinics as Optum targets faster growth and stronger profitability.

Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Notable Tuesday Option Activity: AMGN, VST, DELL

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Amgen Inc (Symbol: AMGN), where a total volume of 24,919 contracts has been traded thus far today, a contract volume which…

Noteworthy Tuesday Option Activity: UNH, MSFT, ADI

Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in UnitedHealth Group Inc (Symbol: UNH), where a total of 29,842 contracts have traded so far, representing approximately 3.0 million…

Boston Scientific misses 2026 guidance after cyberattack

Stocks making the biggest moves midday: Amgen, Qualcomm, Expedia, CoreWeave & more

Here are some of the companies making headlines in midday trading.

European shares muted as oil rally fuels caution; Novartis tumbles

Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?

Pharma major Novartis falls 10% after three drug trial setbacks

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.

Zoetis (ZTS) Shares Drop After Earnings Revision

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.

S&P 500 Movers: AMGN, HONIV

In early trading on Tuesday, shares of Honeywell International topped the list of the day's best performing components of the S&P 500 index, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst…

Dow Movers: AMGN, HONIV

In early trading on Tuesday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the…

Nasdaq 100 Movers: AMGN, HONIV

In early trading on Tuesday, shares of Honeywell International topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain. And the worst…

Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now